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ombitasvir/dasabuvir) +/- ribavirin compared with Harvoni® (sofosbuvir/ledipas-
vir) in the United States. METHODS: A cost-effectiveness Markov model, based 
on previous HCV models, had 13 health states: 8 disease progression states (F0-
F4, decompensated cirrhosis, hepatocellular carcinoma, and liver transplant), 3 
sustained virologic response states, and 2 mortality states (liver-related and non-
liver-related death). Transition rates were obtained from previous models. Adverse 
events, treatment-related disutility, and efficacy rates were based on phase 3 clini-
cal trials. Baseline patient characteristics were derived from AbbVie 3D phase 3 
clinical trials. Treatment durations were 24 weeks for GT1a experienced cirrhotic 
patients with AbbVie 3D and 8 weeks for 26% of GT1 treatment naïve patients with 
Harvoni. Direct medical costs were based on a systematic literature review and drug 
costs were based on December 2014 Red Book. The model was run over a lifetime 
horizon, discounting at 3% annually. Outcomes were measured in quality-adjusted 
life-years (QALYs). Probabilistic simulation analysis (PSA) was conducted by varying 
all parameters simultaneously. RESULTS: AbbVie 3D resulted in discounted lifetime 
costs per patient of $99,753 and 16.20 QALYs. Harvoni resulted in lifetime costs of 
$108,430 and 16.18 QALYs. With lower costs (-$8,677) and higher QALYs (0.02), AbbVie 
3D dominated Harvoni. AbbVie 3D was superior in 98.4% of PSA simulations when 
QALYs were valued at $100,000 each. CONCLUSIONS: With higher QALYs and lower 
costs, AbbVie 3D dominated Harvoni in GT1-HCV-infected patients.
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OBJECTIVES: Evaluate the cost-effectiveness of universal rotavirus vaccination of 
children below age of five years old in the Philippine setting METHODS: We developed 
an age-stratified dynamic transmission model which compared four settings (baseline 
of no vaccine with 34% exclusive breastfeeding rate (EBR), two-dose monovalent vac-
cine (RV1), three-dose pentavalent vaccine (RV5), and no vaccine with 80% EBR) in the 
Philippine population over a 5-year time horizon. Model parameters such as cost and 
vital statistics were Philippine specific and other parameters such as vaccine efficacy 
and utility were extrapolated from literature. Univariate one-way and multivariate 
probabilities sensitivity analyses were conducted. RESULTS: Compared to baseline, 
the model showed that vaccination could lead to significant reduction in rotaviral 
morbidity and mortality in the 0 to < 5 age group as well as inducing herd immunity in 
the older groups. The incremental cost-effectiveness ratios (ICER) of vaccination ver-
sus baseline from a societal perspective were US$ 13,184/DALY for RV1 and US$ 11,836/
DALY for RV5; these are higher than the the current government cost-effectiveness 
threshold equal to the Philippine GNI per capita of US$ 3,134. Comparing 80% EBR 
to baseline, ICER is US$ 256,417/DALY. ICERs were sensitive to changes in case fatal-
ity, proportion of diarrhea cases due to rotavirus, and vaccine efficacy. The vaccine 
was cost-effective in less than 10% of 5000 Monte Carlo simulations. We estimated 
cost-effective prices of US$ 2.85/dose RV1 and US$ 1.96/dose RV5 which were lower 
than the current price of US$ 9.85/dose RV1 and US$ 6.43/dose RV5. CONCLUSIONS: 
Despite herd immunity benefits, universal vaccination using either RV1 or RV5 is 
unlikely to be cost-effective, at current tendered prices, for the Philippine setting, 
despite the herd immunity benefits. It might be due to comparatively low case-fatality 
rates. Current prices need to be decreased around 70% to achieve cost-effectiveness.
PGI23
cost effectIveness of dAclAtAsvIr/AsUnAPrevIr versUs 
PeGInterferon/rIbAvIrIn And ProteAse InhIbItors for the treAtment 
of hePAtItIs c GenotyPe 1b In chIle
Vargas C.1, Espinoza M.A.1, Giglio A.2, Soza A.3
1Pontificia Universidad Catolica de Chile, Santiago, Chile, 2Complejo Asistencial SÃ³tero del RÃo, 
Santiago, Chile, 3Pontificia Universidad CatÃ³lica de Chile, Santiago, Chile
OBJECTIVES: To assess the cost-effectiveness of daclatasvir plus asunaprevir 
(DCV/ASV) versus peginterferon plus ribavirin (PR) and first generation protease 
inhibitors (PIs) for the treatment of patients with hepatitis C genotype 1b, from the 
perspective of the Chilean public healthcare system. METHODS: A Markov cohort 
model (MONARCH) was built to estimate the expected costs in Chilean pesos (CL$) 
and benefits in quality adjusted life years (QALYs) from aggregated data. Efficacy 
was obtained from a mixed-treatment comparison study and costs were estimated 
from local sources. Utilities were estimated from the literature. A time horizon 
of 46 years and a 3% discount rate was considered for costs and outcomes. Three 
groups of patients were examined: untreated (naïve), partial responders and non-
responders. The ICER in naive patients is presented for a range of DCV/ASV prices. 
Deterministic and probabilistic sensitivity analyses were performed. RESULTS: PIs 
were extendedly dominated by DCV/ASV. In naïve patients the ICER of DCV/ASV 
compared to PR was CL$ 15,696,479/QALY (US$26,160/QALY) at a treatment price 
of CL$48,000,000 (US$79,200); CL$10,751,318/QALY (US$17,918/QALY) at a price 
of CL$36,000,000 (US$60,000); CL$5,950,954/QALY (US$9,918/QALY) at a price of 
CL$24,000,000 (US$40,000); and CL$1,278,270/QALY (US$2,130/QALY) at a price of 
CL$12,000,000 (US$20,000). Whilst the probability of cost-effectiveness at a price 
of CL$36,000,000 was 59%, there is a 45% probability that DCV/ASV dominates PR 
if the price was CL$12,000,000. The ICER for partial responders was CL$6,082,698/
QALY (US$10,137/QALY) and for non-responders CL$6,603,023/QALY (US$11,005/
QALY) at a DCV/ASV price of CL$36,000,000. The ICER was more sensitive to the 
discount rate, efficacy of DCV/ASV and the utility of the sustained viral response 
state in cirrhotic patients CONCLUSIONS: DCV/ASV can be considered cost-
effective at some particular price range. These results provide decision makers 
useful information about the value of incorporating these drugs into the public 
Chilean healthcare system.
compared to infliximab was $3.5 million/QALY. Certolizumab pegol and vedolizumab 
were eliminated by extended dominance. In comparison between infliximab and 
active control, the model was robust to all variables in one-way sensitivity analysis. 
Results comparing adalimumab and infliximab were sensitive to utility values. In 
the PSA, infliximab was 99.6% cost-effective compared to active control; however, 
adalimumab was only 2.6% cost-effective. CONCLUSIONS: Infliximab is cost-effective 
relative to active control, whereas, adalimumab is not when compared to infliximab. 
Other studies have reported varying results which highlights the importance for 
further work in this area.
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OBJECTIVES: Up-to-date estimation of healthcare costs in Ulcerative Colitis (UC) and 
Crohn’s Disease (CD) patients is crucial to inform budgeting and resource allocation 
decisions. Recent introduction of biologic therapies rendered previous cost studies 
with standard therapy obsolete. We sought to determine healthcare costs in a con-
secutive sample of real-world UC and CD patients managed in a specialized facility 
in a tertiary referral center in Israel. METHODS: Data-bases of patients enrolled in an 
ongoing socio-economic study were mined to determine healthcare resource utiliza-
tion during the years 2012 and 2013. This included direct charges for in-patients and 
out-patients, hospitalizations, investigations and medical and surgical treatments. 
Prices were obtained from the Ministry of Health Tariff (12/2014) and expressed as US 
$. Data express costs related to UC and CD patients, excluding any treatments for co-
morbidities. RESULTS: This adult cohort had a mean age of 45.1 ± 17.2 years, with M:F 
ratio 1.04. The mean [median] healthcare cost/patient was: UC, 2012 (n= 273): $1,710 
[$847], 2013 (n= 280): $1,983 [$916]; CD, 2012 (n= 263): $4,231 [$1,450], 2013 (n= 280): 
$4,568 [$1,169]. Between-year differences in costs were not statistically significant. 
Over the two-year period, the major cost drivers in UC were procedures (37.3% of 
costs), consultations (20.4%), biologic medication (17.8%), standard medication (13.5%) 
and hospitalization (9.4%). In CD, the cost drivers were biologic medication (47.4%), 
surgery (13.8%), procedures (12.1%), consultations (11.21%), hospitalization (10.7%) and 
standard medication (4.8%). Mean biologic medication cost/patient in UC increased 
from $293 in 2012 to $352 in 2013; and for CD from $1882 to $2289 respectively. This 
paralleled an increase in the number of patients receiving biologic medication from 
65 in 2012 to 76 in 2013; of these, 81% had CD. CONCLUSIONS: CD patients engender 
much higher healthcare costs that those with UC. Expensive biologic medication 
now becomes the major cost driver in CD, but not UC, patients in the current era.
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OBJECTIVES: Although the high cost burden of chronic hepatitis C (CHC) has been 
described in the literature, there is a lack of data on the assessment of characteristics 
associated with high healthcare utilizers. The purpose of this study was to identify 
demographics and clinical characteristics associated with high healthcare utilizers 
and liver disease progression among CHC patients. METHODS: Health insurance 
claims from 60 self-insured US companies were analyzed (01/2001-03/2013). Adult 
patients with ≥ 2 CHC claims (ICD-9-CM: 070.44 or 070.54), ≥ 6 months of continu-
ous insurance coverage before the first CHC diagnosis and ≥ 36 months after were 
included. Patients with HIV were excluded. Demographics and baseline comorbidi-
ties including CHC- and non-CHC-related conditions were described. Generalized 
estimating equations with logit link for binary outcomes were used to identify the 
most predictive demographics and clinical characteristics of being in the 20% of 
patients with the highest healthcare resource utilization (HRU). Predictive factors of 
liver disease progression were also identified. RESULTS: The mean age of the study 
population (N= 4,898) was 52.4 years and 39.4% were female. Compensated cirrhosis, 
ESLD and both CHC- and non CHC-related comorbidities were strong predictors of 
high healthcare costs, with odds ratios (ORs; 95%CI) for ESLD, ≥ 2 CHC-related, and ≥ 2 
non CHC-related comorbidities of 3.31 (2.80-3.92), 2.78 (2.47-3.12), and 2.18 (1.75-2.71), 
respectively. CHC- and non CHC-related comorbidities were also strong predictors of 
liver disease progression with ORs (95%CI) for ≥ 2 CHC-related and ≥ 2 non CHC-related 
comorbidities of 2.18 (1.83-2.60) and 1.50 (1.14-1.97), respectively. CONCLUSIONS: This 
real-world study suggests that CHC patients with the highest HRU and costs had a 
high level of comorbidity at baseline and that non-CHC conditions are strong predic-
tors of high healthcare costs. Liver disease severity alone does not fully predict high 
consumption of HRU, although when present it is a predictor of high HRU.
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OBJECTIVES: Interferon (INF)-free therapies for the treatment of hepatitis C virus 
(HCV) offer better viral clearance rates and safety profiles than older therapies 
but are priced higher. These therapies have also been shown to have favorable 
cost-effectiveness profiles compared with older therapies; however, the cost-
effectiveness of INF-free regimens relative to each other is unclear. The objective 
of this study was to assess the cost-effectiveness of treating genotype 1 (GT1) HCV 
patients with AbbVie 3D (paritaprevir [developed by AbbVie and Enanta] /ritonavir/
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expenditures in the ≤ 62 cohort. CONCLUSIONS: HE is a growing problem in the US 
and becoming increasingly costly condition for the Medicare population.
GAstroIntestInAl dIsorders - Patient-reported outcomes & Patient  
Preference studies
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OBJECTIVES: Estimating health-related utility weights in Crohn’s Disease (CD) 
patients is crucial for assessing the cost-effectiveness of new pharmaceutical 
interventions. However, values used in these analyses are usually based on sec-
ondary data and vary substantially among studies. We estimated utility weights 
in a consecutive sample of real-world CD patients. METHODS: Patients enrolled 
in an ongoing socio-economic study of CD in the Israeli adult patient population 
completed the self-administered SF-36 questionnaire and were assessed for their 
current clinical status, including the Harvey-Bradshaw Index (HBI) of disease sever-
ity. Patients were classified to one of the four disease states: disease remission 
(HBI< 5); mild disease (HBI 5-7); moderate disease (HBI 8-16), and severe disease 
(HBI> 16). For each patient enrolled we calculated a utility weight using the SF-6D 
preference-based scoring system developed by Brazier et al. RESULTS: The cohort 
comprised of 373 patients: (39.4% male), with mean age of 37.8 (±14.2) years, 14.5 
(±2.8) years of education, and 11.8 (±9.0) years elapsed since first diagnosis. The 
average HBI was 6.7 (± 5.6); 148 patients were in remission state, 79 had mild disease, 
121 moderate and 25 severe disease. The SF-6D utility weights were correlated with 
the HBI (-0.341; p< 0.0001). The mean utility weights for each disease state were 
as follows: disease remission: 0.720 (±0.141); mild disease; 0.700 (±0.123); moder-
ate disease: 0.603 (±0.109); severe disease: 0.531 (±0.135); p< 0.001. The significant 
predictors of utility weights in a multivariable regression analysis were the HBI 
(β = -0,440; p< 0.001), years of education (β = 0.104; p= 0.034), and time since diagnosis 
(β = 0.150; p= 0.007); (R2 = 0.246). CONCLUSIONS: CD patients suffer from a deprived 
quality of life even in the remission and mild stages of the disease. Utility weights 
for these patients were generally lower as compared to values used in published 
cost-effectiveness analyses. These values should be considered when assessing the 
value for money of future interventions for CD.
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OBJECTIVES: Eosinophilic Esophagitis (EoE) is an inflammatory disorder that can 
have an impact on quality of life in individuals. The psychometric properties of 
the Dysphagia Symptom Questionnaire (DSQ) were assessed in a Phase 2, ran-
domized, double-blind, placebo controlled study of oral budesonide suspension 
with an open-label extension program. METHODS: The evaluation focused on three 
items of the DSQ. Psychometric data were analyzed against the FDA guidance and 
included item level analysis as well as score validation including floor/ceiling, item 
discrimination, construct validity (concurrent validity and known group’s method), 
test-retest reliability, responsiveness, and calculation of minimally important differ-
ences (MID). RESULTS: Patients were 69% male, 62% age ≥ 18, 95% white. Test-retest 
reliability was strong (r= 0.82). Floor/ceiling levels were below the criteria (≤ 9%) for all 
items (range 6.5-8.6%). There was strong item discrimination with 98.1% of patients 
indicating dysphagia in the quartile of DSQ scores. Physician’s global ratings of 
severity and EoE symptom scores were consistent with monotonically increasing 
DSQ scores. Anchor-based MIDs were 6.5 “a little better” and 13.5 “better” respec-
tively. CONCLUSIONS: The DSQ is a reliable and valid measure able to clinically 
discriminate patients along the continuum of dysphagia severity.
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OBJECTIVES: To study the variations in self-reported health status of mainland 
Chinese patients with chronic hepatitis B (CHB) prior to initiating nucleos(t)ide 
analogues (NUC) treatment. METHODS: This study drew the baseline data of the 
EVOLVE study, an ongoing observational clinical study of NUCs for treating CHB 
patients with or without compensated cirrhosis in China. All patients underwent a 
basket of tests for liver functions and information on their clinical characteristics, 
life styles, health status (using the EQ-5D-3L questionnaire), and socio-economic 
status was obtained from medical records or personal interviews. Variations in self-
reported health problems and global health were analyzed with logistic and linear 
regression models, respectively, to identify significant predictors using a stepwise 
selection method. RESULTS: Two thousand nine hundred and fifty-eight of the 
3,434 NUC naïve CHB patients enrolled from 63 hospitals across China (mean age: 
39.3 years; male: 73.1%; HBeAg positive: 61.1%; compensated cirrhosis: 20.4%) were 
included in this analysis. Among those, less than 2% reported problems in mobility, 
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OBJECTIVES: The approval of direct-acting antivirals for Interferon-free treatment 
revolutionized the therapy of chronic Hepatitis C infection. As of August 2014, two 
treatment regimens for genotype 1 infection received approval in the European 
Union: Sofosbuvir and Ribavirin for 24 weeks and Sofosbuvir and Simeprevir with or 
without Ribavirin for 12 weeks. We aim to analyze the cost-effectiveness of both reg-
imens in Germany. METHODS: We set up a Markov model with a lifetime horizon to 
simulate immediate treatment success and long-term disease progression for treat-
ment-naive patients. The model analyzes both shortterm and longterm costs and 
benefits from the perspective of the German Statutory Health Insurance. We apply 
the efficiency frontier method, which was suggested by German Institute for Quality 
and Efficiency in Health Care for cost-effectiveness analysis in Germany. RESULTS: 
The efficiency frontier is defined by dual therapy and first generation direct-acting 
antiviral Boceprevir, yielding a maximum of € 1,447.69 per additional percentage 
point of sustained virologic response gained. Even without rebates, Sofosbuvir/
Simeprevir is very close with € 1,560.13 per additional percentage point. It is both 
more effective and less expensive than Sofosbuvir/Ribavirin. CONCLUSIONS: In 
addition to higher sustained virologic response rates, new direct-acting antivirals 
save long-term costs by preventing complications such as liver cirrhosis, hepa-
tocellular carcinoma and ultimately liver transplants, thereby offsetting part of 
higher drug costs. Our findings are in line with the guidance published by German 
Society for Gastroenterology, Digestive and Metabolic Diseases, which recommends 
Sofosbuvir/Simeprevir for Interferon ineligible or intolerant patients.
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OBJECTIVES: This study reports the long-term cost per sustained virologic response 
(SVR) with Viekira Pak (ombitasvir, paritaprevir and ritonavir, dasabuvir) with and 
without ribavirin and standard of care in the US, including sofosbuvir plus sime-
previr (SOF+SMV) and sofosbuvir plus peg-interferon and ribavirin (SOF+PR), among 
patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection. METHODS: 
A Markov cost-effectiveness model was used to estimate the long-term cost of HCV. 
The analysis modeled independent cohorts of GT1 HCV patients over a lifetime 
horizon with annual cycles from a US payer perspective. Liver disease progression 
was assessed based on previous natural history model. Direct medical costs (in 2014 
prices and discounted at 3% per year) were obtained from the published literature. 
Efficacy and safety data were obtained from published clinical trials. SVR rates 
were stratified by patient treatment history, cirrhosis status, and sub-genotype, 
where available. Long-term cost per SVR for a patient segment was calculated by 
dividing total cost of HCV over patient’s lifetime by the mean SVR rate in that 
patient segment. RESULTS: The long-term cost per SVR with Viekira Pak ranged 
from $88,305 to $94,433 in GT1 non-cirrhotic patients (12-week regimen), $125,748 
(12-week) to $216,520 (24-week) in GT1 cirrhotic patients, $94,433 to $141,413 in GT1a 
and $88,332 to $125,748 in GT1b treatment-naïve patients (12-week). Long-term 
cost per SVR with SOF+SMV was $164,725 (12-week) in GT1 non-cirrhotic patients, 
and $341,569 (24-week) in GT1 cirrhotic patients, all treatment histories combined. 
Long-term cost per SVR with SOF+PR was $116,713 in GT1a and $134,561 in GT1b 
naïve patients (12-week). CONCLUSIONS: The long-term cost per SVR was lower in 
non-cirrhotic than in cirrhotic patients across all regimens. The results of this study 
suggest that the use of Viekira Pak is a clinically and economically viable strategy 
for GT1 HCV treatment.
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OBJECTIVES: Hepatic encephalopathy (HE) is a major complication of liver disease 
and is becoming more problematic in an aging population with cirrhosis. Medicare 
is a United States (US) government-sponsored health insurance program that guar-
antees access to healthcare for all individuals 65 or older, or who are younger with 
disability. The objective of this study was to estimate the annual healthcare expen-
ditures of patients with HE from a Medicare perspective. METHODS: Inpatient, 
Outpatient, and Master Beneficiary Research Identifiable Files (RIFs) from the 
Medicare 5% Sample were utilized for this study. Medicare 5% Sample is a nation-
ally representative sample of healthcare claims data for the Medicare population. 
RIFs include procedure codes, diagnosis codes, reimbursement, and demographic 
information. To be eligible patients had to have a primary diagnosis code of HE dur-
ing an inpatient hospitalization. Healthcare utilization/expenditures for inpatient 
(IP) and outpatient (OP) procedures for the calendar year 2012 were estimated overall 
and by age cohorts: ≤ 62, 63-67, 68-72, 73-77, 78-82, 83+. RESULTS: A total of 1,113 
patients were identified with HE in 2012 (47% were male). 27% of the patients were 
≤ 62 years of age while 11% were 83 or older. The most common chronic comorbid 
condition was hypertension (75%) and 41% had renal failure. The mean total number 
of visits per HE patient was 13.4 (Mean number of IP and OP visits = 2.4 and 11.0, 
respectively) and varied across age cohorts 14.6 in the ≤ 62 cohort to 10.7 in the 83+ 
cohort; p< 0.0001. For patients who had an IP visit the mean length of stay was 5.9 
days. Mean inpatient expenditures ranged from $25,364 to $58,625 with the highest 
